Keyphrases
Phosphoinositide 3-kinase (PI3K)
41%
Genome-driven Oncology
41%
Precision Oncology
41%
Targeted Therapy
36%
Genotype
28%
High-grade Glioma
20%
Estrogen Receptor
20%
PI3K Inhibitor
20%
Serial Analysis
20%
TP53 mutation
20%
Druggability
20%
Hormone Receptor-positive Breast Cancer
20%
Artificial Intelligence
20%
Granulosa Cells
20%
Transformer Model
20%
Bidirectional Encoder Representations from Transformers
20%
Hospital Care
20%
PLX8394
20%
Early-stage Lung Cancer
20%
Cancer Genomic Data
20%
Support System
20%
Distant Metastasis
20%
Sequence Data
20%
Therapeutic Target
20%
Genomic Landscape
20%
Real-world Outcomes
20%
Ovarian Cancer
20%
Activin
20%
Receptor Function
20%
Advanced Solid Tumors
20%
Phase I Study
20%
Informatic Platforms
20%
POLST
20%
Genomic Analysis
20%
Treatment Recommendations
20%
First-in-human
20%
Physician Support
20%
Clinical Trials
20%
Clinical Genomics
20%
Tailored Therapy
20%
Therapy Selection
20%
Molecular Tumor Board
20%
Tumor
15%
Tumor Sequencing
15%
Median Time
13%
PIK3CA
13%
Do-not-resuscitate Orders
11%
Readmission
11%
Oncology
11%
Element Model
11%
Medicine and Dentistry
Neoplasm
74%
Breast Cancer
65%
Oncology
62%
Clinical Trial
57%
Phosphoinositide 3-Kinase
41%
Targeted Therapy
37%
Malignant Neoplasm
31%
Lung Cancer
23%
Life Sustaining Treatment
20%
Cyclic AMP Dependent Protein Kinase
20%
Gamma Urogastrone
20%
Solid Malignant Neoplasm
20%
Side Effect
20%
Epidermal Growth Factor Receptor
20%
Ovarian Cancer
20%
Hospital Care
20%
Scanning Tunneling Microscopy
20%
Epidermal Growth Factor Receptor 3
20%
Granulosa Cell
20%
Ganglioglioma
20%
Hormone Receptor
20%
Activin
20%
Estrogen Receptor
20%
Distant Metastasis
20%
Triple Negative Breast Cancer
20%
COVID-19
20%
Adjuvant Chemotherapy
20%
Resuscitation
20%
Decision Making
20%
Activin A
15%
Non Small Cell Lung Cancer
12%
Cachexia
10%
Lean Body Weight
10%
Six Minute Walk Test
10%
Bone Morphogenetic Protein 9
10%
Oncologist
10%
Overall Survival
9%
Disease
8%
Cancer Types
7%
Tumor Biology
6%
Genome Sequencing
6%
Translating (Language)
6%
Advanced Cancer
6%
Medical Oncology
6%
Next Generation Sequencing
6%
Antineoplastic Activity
5%
Pharmacokinetics
5%
Cancer Treatment
5%
Adverse Event
5%
Pathogenicity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Malignant Neoplasm
83%
Clinical Trial
54%
Breast Cancer
41%
Phosphatidylinositol 3 Kinase
41%
Gamma Urogastrone
20%
Estrogen Receptor
20%
Side Effect
20%
Chemotherapy
20%
Solid Malignant Neoplasm
20%
Epidermal Growth Factor Receptor 3
20%
Cyclic AMP Dependent Protein Kinase
20%
Ovary Cancer
20%
Combination Therapy
20%
Epidermal Growth Factor Receptor
20%
Hormone Receptor
20%
Triple Negative Breast Cancer
20%
Activin
20%
Scanning Tunneling Microscopy
20%
Activin A
15%
Cachexia
10%
Bone Morphogenetic Protein 9
10%
Clinical Study
6%
Overall Survival
6%
Preclinical Study
6%
Tumor Suppressor Protein
6%
Combination Drug
6%
Human
6%
Disease
5%
Pharmacokinetics
5%
Maximum Tolerated Dose
5%
Receptor
5%
Gingiva Bleeding
5%
Epistaxis
5%
Antitumor Activity
5%
Follitropin
5%
Bleeding
5%
Adverse Event
5%